Product Description
FPI-1434 is a radioimmunoconjugate designed to target and deliver alpha emitting medical isotopes to cancer cells expressing IGF-1R, a receptor that is overexpressed on many tumor types. FPI-1434 utilizes Fusion's Fast-Clear linker to connect a human monoclonal antibody that targets IGF-1R with actinium-225, a powerful alpha-emitting isotope with desirable half-life and decay chain properties. (Sourced from: https://ir.fusionpharma.com/2022-06-09-Fusion-Pharmaceuticals-Provides-Updates-on-FPI-1434-and-FPI-1966-Clinical-Programs)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fusion Pharmaceuticals
Company Location: HAMILTON A6 L8P 0A6
Company CEO: John Valliant
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Fusion Pharmaceuticals presented P1 Oncology Solid Tumor Unspecified results on 2024-01-04 for FPI-1434
Highest Development Phases
Phase 2: Adrenocortical Carcinoma|Cervical Cancer|Endometrial Cancer|Head and Neck Cancer|Ovarian Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Uveal Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| FPX-01-01 | P2 |
Recruiting |
Uveal Melanoma|Adrenocortical Carcinoma|Endometrial Cancer|Cervical Cancer|Head and Neck Cancer|Triple Negative Breast Cancer|Squamous Cell Carcinoma|Ovarian Cancer |
2025-06-01 |
12% |
2024-11-30 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/26/2024 |
News Article |
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences |
|
02/26/2024 |
News Article |
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences |
|
02/16/2024 |
News Article |
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy |
|
02/16/2024 |
News Article |
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy |